Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types

Treatment Name: Ribociclib (Kisqali®) + Fulvestrant (Faslodex®)

Ribociclib (Kisqali®) + Fulvestrant (Faslodex®) is a Treatment Regimen for Breast Cancer - metastatic

Thank you for visiting our Ribociclib (Kisqali®) + Fulvestrant (Faslodex®) page.

  • If you are interested in seeing the full treatment regimen page for Ribociclib (Kisqali®) + Fulvestrant (Faslodex®) sooner rather than later, please cast your vote for Ribociclib (Kisqali®) + Fulvestrant (Faslodex®).
  • Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for Ribociclib (Kisqali®) + Fulvestrant (Faslodex®) shown below will prove useful in the meantime.

Thank you for your continued support!

The ChemoExperts Team


1) Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-2472.

Created: February 16, 2019 Updated: February 16, 2019

What is Breast Cancer - metastatic?

What is Metastatic Breast Cancer?
A disease of the milk-producing glands known as lobules, milk ducts, or other cells found in the breast. Metastatic breast cancer is one that has moved from the breast to other areas of the body, which may include the brain, liver, or bone. Breast cancer is one of the most common types of cancers in women, but may rarely affect men as well. Known causes of breast cancer include genetic causes, such as the BRCA mutation, or obesity. The effectiveness of the treatment may depend upon the stage at diagnosis.

Types of metastatic breast cancer:
1. Hormone-receptor positive or negative (60 - 65% of patients)

  • Estrogen Receptor positive (ER)+ or negative (ER)-
  • Progestin Receptor positive (PR)+ or negative (PR)-

2. Hormone Epidermal growth factor Receptor-2 (HER-2) positive or negative (20 - 25% of patients)

  • HER-2 +
  • HER-2 -

3. Triple Negative (15 - 18% of patients)

  • ER- and PR- and (HER-2)-
NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

Common starting doses for Ribociclib (Kisqali®) + Fulvestrant (Faslodex®)

  • Usual ribociclib starting dose: 600 mg (three 200 mg tablets) by mouth daily for 21 consecutive days, followed by a 7-day no ribociclib rest period
  • Fulvestrant intramuscular (I.M.) injection weekly for 3 weeks, then monthly thereafter